Terms: = Germ cell tumor AND JAK1, ENSG00000162434, P23458, JTK3, JAK1B, JAK1A, 3716 AND Treatment
32 results:
1. Ruxolitinib enhances cytotoxic and apoptotic effects of temozolomide on glioblastoma cells by regulating WNT signaling pathway-related genes.
Goker Bagca B; Ozates NP; Biray Avci C
Med Oncol; 2022 Dec; 40(1):37. PubMed ID: 36460932
[TBL] [Abstract] [Full Text] [Related]
2. Integrated proteogenomic characterization across major histological types of pituitary neuroendocrine tumors.
Zhang F; Zhang Q; Zhu J; Yao B; Ma C; Qiao N; He S; Ye Z; Wang Y; Han R; Feng J; Wang Y; Qin Z; Ma Z; Li K; Zhang Y; Tian S; Chen Z; Tan S; Wu Y; Ran P; Wang Y; Ding C; Zhao Y
Cell Res; 2022 Dec; 32(12):1047-1067. PubMed ID: 36307579
[TBL] [Abstract] [Full Text] [Related]
3. CAR T cell killing requires the IFNγR pathway in solid but not liquid tumours.
Larson RC; Kann MC; Bailey SR; Haradhvala NJ; Llopis PM; Bouffard AA; Scarfó I; Leick MB; Grauwet K; Berger TR; Stewart K; Anekal PV; Jan M; Joung J; Schmidts A; Ouspenskaia T; Law T; Regev A; Getz G; Maus MV
Nature; 2022 Apr; 604(7906):563-570. PubMed ID: 35418687
[TBL] [Abstract] [Full Text] [Related]
4. Effects of Vitexin, a Natural Flavonoid Glycoside, on the Proliferation, Invasion, and Apoptosis of Human U251 Glioblastoma cells.
Huang J; Zhou Y; Zhong X; Su F; Xu L
Oxid Med Cell Longev; 2022; 2022():3129155. PubMed ID: 35281458
[TBL] [Abstract] [Full Text] [Related]
5. Targeting the gp130/STAT3 Axis Attenuates tumor Microenvironment Mediated Chemoresistance in Group 3 Medulloblastoma cells.
Sreenivasan L; Li LV; Leclair P; Lim CJ
Cells; 2022 Jan; 11(3):. PubMed ID: 35159191
[TBL] [Abstract] [Full Text] [Related]
6. Immunostimulatory bacterial antigen-armed oncolytic measles virotherapy significantly increases the potency of anti-PD1 checkpoint therapy.
Panagioti E; Kurokawa C; Viker K; Ammayappan A; Anderson SK; Sotiriou S; Chatzopoulos K; Ayasoufi K; Johnson AJ; Iankov ID; Galanis E
J Clin Invest; 2021 Jul; 131(13):. PubMed ID: 34196308
[TBL] [Abstract] [Full Text] [Related]
7. Mutations in the IFNγ-JAK-STAT Pathway Causing Resistance to Immune Checkpoint Inhibitors in Melanoma Increase Sensitivity to Oncolytic Virus treatment.
Nguyen TT; Ramsay L; Ahanfeshar-Adams M; Lajoie M; Schadendorf D; Alain T; Watson IR
Clin Cancer Res; 2021 Jun; 27(12):3432-3442. PubMed ID: 33593882
[TBL] [Abstract] [Full Text] [Related]
8. Incidence and Mortality of Second Primary Cancers in Danish Patients With Retinoblastoma, 1943-2013.
Gregersen PA; Olsen MH; Urbak SF; Funding M; Dalton SO; Overgaard J; Alsner J
JAMA Netw Open; 2020 Oct; 3(10):e2022126. PubMed ID: 33090227
[TBL] [Abstract] [Full Text] [Related]
9. TROY signals through jak1-STAT3 to promote glioblastoma cell migration and resistance.
Ding Z; Kloss JM; Tuncali S; Tran NL; Loftus JC
Neoplasia; 2020 Sep; 22(9):352-364. PubMed ID: 32629176
[TBL] [Abstract] [Full Text] [Related]
10. Inhibition of MICA and MICB Shedding Elicits NK-cell-Mediated Immunity against tumors Resistant to Cytotoxic T cells.
Ferrari de Andrade L; Kumar S; Luoma AM; Ito Y; Alves da Silva PH; Pan D; Pyrdol JW; Yoon CH; Wucherpfennig KW
Cancer Immunol Res; 2020 Jun; 8(6):769-780. PubMed ID: 32209637
[TBL] [Abstract] [Full Text] [Related]
11.
Yogev O; Almeida GS; Barker KT; George SL; Kwok C; Campbell J; Zarowiecki M; Kleftogiannis D; Smith LM; Hallsworth A; Berry P; Möcklinghoff T; Webber HT; Danielson LS; Buttery B; Calton EA; da Costa BM; Poon E; Jamin Y; Lise S; Veal GJ; Sebire N; Robinson SP; Anderson J; Chesler L
Cancer Res; 2019 Oct; 79(20):5382-5393. PubMed ID: 31405846
[TBL] [Abstract] [Full Text] [Related]
12. Targeting Upstream Kinases of STAT3 in Human Medulloblastoma cells.
Wei J; Ma L; Li C; Pierson CR; Finlay JL; Lin J
Curr Cancer Drug Targets; 2019; 19(7):571-582. PubMed ID: 30332965
[TBL] [Abstract] [Full Text] [Related]
13. Surgical-site infection following lymph node excision indicates susceptibility for lymphedema: A retrospective cohort study of malignant melanoma patients.
Jørgensen MG; Toyserkani NM; Thomsen JB; Sørensen JA
J Plast Reconstr Aesthet Surg; 2018 Apr; 71(4):590-596. PubMed ID: 29246739
[TBL] [Abstract] [Full Text] [Related]
14. Acquired IFNγ resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions.
Sucker A; Zhao F; Pieper N; Heeke C; Maltaner R; Stadtler N; Real B; Bielefeld N; Howe S; Weide B; Gutzmer R; Utikal J; Loquai C; Gogas H; Klein-Hitpass L; Zeschnigk M; Westendorf AM; Trilling M; Horn S; Schilling B; Schadendorf D; Griewank KG; Paschen A
Nat Commun; 2017 May; 8():15440. PubMed ID: 28561041
[TBL] [Abstract] [Full Text] [Related]
15. Mechanisms of Resistance to Immune Checkpoint Antibodies.
Ramos RN; Piaggio E; Romano E
Handb Exp Pharmacol; 2018; 249():109-128. PubMed ID: 28315073
[TBL] [Abstract] [Full Text] [Related]
16. [Immunotherapy of cancer with checkpoint inhibitors : Not only in malignant melanoma].
Neubauer A
Internist (Berl); 2017 Apr; 58(4):409-423. PubMed ID: 28303311
[TBL] [Abstract] [Full Text] [Related]
17. Acrylamide inhibits cellular differentiation of human neuroblastoma and glioblastoma cells.
Chen JH; Chou CC
Food Chem Toxicol; 2015 Aug; 82():27-35. PubMed ID: 25959841
[TBL] [Abstract] [Full Text] [Related]
18. Cucurbitacin-I inhibits Aurora kinase A, Aurora kinase B and survivin, induces defects in cell cycle progression and promotes ABT-737-induced cell death in a caspase-independent manner in malignant human glioma cells.
Premkumar DR; Jane EP; Pollack IF
Cancer Biol Ther; 2015; 16(2):233-43. PubMed ID: 25482928
[TBL] [Abstract] [Full Text] [Related]
19. Progesterone-induced blocking factor is hormonally regulated in human astrocytoma cells, and increases their growth through the IL-4R/jak1/STAT6 pathway.
González-Arenas A; Valadez-Cosmes P; Jiménez-Arellano C; López-Sánchez M; Camacho-Arroyo I
J Steroid Biochem Mol Biol; 2014 Oct; 144 Pt B():463-70. PubMed ID: 25218441
[TBL] [Abstract] [Full Text] [Related]
20. AZD1480 delays tumor growth in a melanoma model while enhancing the suppressive activity of myeloid-derived suppressor cells.
Maenhout SK; Du Four S; Corthals J; Neyns B; Thielemans K; Aerts JL
Oncotarget; 2014 Aug; 5(16):6801-15. PubMed ID: 25149535
[TBL] [Abstract] [Full Text] [Related]
[Next]
